Concise review: Induced pluripotent stem cell research in the era of precision medicine

Stem Cells

Volumn 35, Issue 3, 2017, Pages 545-550

  Hamazaki, Takashi ^a   El Rouby, Nihal ^b   Fredette, Natalie C ^c   Santostefano, Katherine E ^c   Terada, Naohiro ^c  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Experimental models; Genomics; Induced pluripotent stem cells

Indexed keywords

GENOME-WIDE ASSOCIATION STUDY; HUMAN; HUMAN GENOME; INDUCED PLURIPOTENT STEM CELL; MONOGENIC DISORDER; PERSONALIZED MEDICINE; PHENOTYPIC VARIATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; CYTOLOGY; GENETICS; METABOLISM; PHENOTYPE; STEM CELL RESEARCH; ARTICLE; CELL DIFFERENTIATION; GENE EDITING; GENOMICS; NONHUMAN;

ANIMALS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECISION MEDICINE; STEM CELL RESEARCH;

EID: 85012988624     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2570     Document Type: Review

References (55)

1. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860–921.
2. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 2001;291:1304–1351.
3. International HapMap Consortium. The international HapMap project. Nature 2003; 426:789–796.
4. International HapMap Consortium, Frazer KA, Ballinger DG et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007;449:851–861.
5. 1000 Genomes Project Consortium, Auton A, Brooks LD et al. A global reference for human genetic variation. Nature 2015; 526:68–74.
6. Welter D, MacArthur J, Morales J et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res 2014;42:D1001–D1006.
7. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372: 793–795.
8. McCarthy M. Obama seeks $213m to fund “precision medicine". BMJ 2015; 350:h587.
9. Yamanaka S. Induced pluripotent stem cells: Past, present, and future. Cell Stem Cell 2012;10:678–684.
10. Wilson KD, Wu JC. Induced pluripotent stem cells. JAMA 2015;313:1613–1614.
11. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014;157:1262–1278.
12. Kim H, Kim J-S. A guide to genome engineering with programmable nucleases. Nat Rev Genet 2014;15:321–334.
13. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861–872.
14. Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318: 1917–1920.
15. Hankowski KE, Hamazaki T, Umezawa A et al. Induced pluripotent stem cells as a next-generation biomedical interface. Lab Invest 2011;91:972–977.
16. Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature 2012;481:295–305.
17. Ebert AD, Yu J, Rose FF et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009;457:277–280.
18. Itzhaki I, Maizels L, Huber I et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011;471:225–229.
19. Juopperi TA, Kim WR, Chiang C-H et al. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington’s disease patient cells. Mol Brain 2012;5:17.
20. Du J, Campau E, Soragni E et al. Length-dependent CTG.CAG triplet-repeat expansion in myotonic dystrophy patient-derived induced pluripotent stem cells. Hum Mol Genet 2013;22:5276–5287.
21. Cayo MA, Cai J, DeLaForest A et al. JD induced pluripotent stem cell-derived hepa-tocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia. Hepatology 2012;56:2163–2171.
22. Fan Y, Luo Y, Chen X et al. Generation of human b-thalassemia induced pluripotent stem cells from amniotic fluid cells using a single excisable lentiviral stem cell cassette. J Reprod Dev 2012;58:404–409.
23. Santostefano KE, Hamazaki T, Biel NM et al. A practical guide to induced pluripotent stem cell research using patient samples. Lab Invest 2015;95:4–13.
24. Yamashita A, Morioka M, Kishi H et al. Statin treatment rescues FGFR3 skeletal dys-plasia phenotypes. Nature 2014;513:507–511.
25. Lancaster M, A Renner M, Martin C-A et al. Cerebral organoids model human brain development and microcephaly. Nature 2013; 501:373–379.
26. Nakano T, Ando S, Takata N et al. Self-formation of optic cups and storable stratified neural retina from human ESCs. Cell Stem Cell 2012;10:771–785.
27. Ozone C, Suga H, Eiraku M et al. Functional anterior pituitary generated in self-organizing culture of human embryonic stem cells. Nat Commun 2016;7:10351.
28. Pastores GM, Hughes DA. Gaucher disease. 1993. Available at http://www.ncbi.nlm.nih.gov/pubmed/20301446. Accessed August 18, 2016.
29. Tayebi N, Stubblefield BK, Park JK et al. Reciprocal and nonreciprocal recombination at the glucocerebrosidase gene region: Implications for complexity in Gaucher disease. Am J Hum Genet 2003;72:519–534.
30. Lachmann RH, Grant IR, Halsall D et al. Twin pairs showing discordance of phenotype in adult Gaucher’s disease. QJM 2004;97:199–204.
31. Mistry PK, Liu J, Sun L et al. Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease. Proc Natl Acad Sci USA 2014;111:4934–4939.
32. Awad O, Sarkar C, Panicker LM et al. Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells. Hum Mol Genet 2015;24:5775–5788.
33. WTCCC. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447: 661–678.
34. Mozaffarian D, Benjamin EJ, Go AS et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. 2015;131:e29–322.
35. Moran AE, Odden MC, Thanataveerat A et al. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med 2015;372:447–455.
36. Rapsomaniki E, Timmis A, George J et al. Blood pressure and incidence of twelve cardiovascular diseases: Lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 2014;383:1899–1911.
37. Mellen PB, Herrington DM. Pharmacogenomics of blood pressure response to antihypertensive treatment. J Hypertens 2005;23: 1311–1325.
38. Biel NM, Santostefano KE, DiVita BB et al. Vascular smooth muscle cells from hypertensive patient-derived induced pluripotent stem cells to advance hypertension pharmacogenomics. Stem Cells Transl Med 2015;4:1380–1390.
39. Johnson JA, Boerwinkle E, Zineh I et al. Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharma-cogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J 2009; 157:442–449.
40. Ebert AD, Kodo K, Liang P et al. Characterization of the molecular mechanisms underlying increased ischemic damage in the aldehyde dehydrogenase 2 genetic polymor-phism using a human induced pluripotent stem cell model system. Sci Transl Med 2014;6:255ra130.
41. Chang EA, Tomov ML, Suhr ST et al. Derivation of ethnically diverse human induced pluripotent stem cell lines. Sci Rep 2015;5: 15234.
42. Hockemeyer D, Jaenisch R. Induced pluripotent stem cells meet genome editing. Cell Stem Cell 2016;18:573–586.
43. Deleidi M, Yu C. Genome editing in pluripotent stem cells: Research and therapeutic applications. Biochem Biophys Res Commun 2016;473:665–674.
44. Soldner F, Stelzer Y, Shivalila CS et al. Parkinson-associated risk variant in distal enhancer of a-synuclein modulates target gene expression. Nature 2016;533:95–99.
45. Vissers LELM, Veltman JA. Standardized phenotyping enhances Mendelian disease gene identification. Nat Genet 2015;47:1222–1224.
46. Akawi N, McRae J, Ansari M et al. Discovery of four recessive developmental disorders using probabilistic genotype and phenotype matching among 4,125 families. Nat Genet 2015;47:1363–1369.
47. Gatto EM, Etcheverry JL, Sanguinetti A et al. Prodromal clinical markers of Parkinson disease in Gaucher disease individuals. Eur Neurol 2016;76:19–21.
48. Ran C, Brodin L, Forsgren L et al. Strong association between glucocerebrosidase mutations and Parkinson’s disease in Sweden. Neurobiol Aging 2016;45:212.e5-212.e11.
49. Sidransky E, Nalls MA, Aasly JO et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 2009;361:1651–1661.
50. Chimienti F, Devergnas S, Pattou F et al. In vivo expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion. J Cell Sci 2006;119:4199–4206.
51. Dupuis J, Langenberg C, Prokopenko I et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010;42:105–116.
52. Strawbridge RJ, Dupuis J, Prokopenko I et al. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes 2011;60:2624–2634.
53. Morris AP, Voight BF, Teslovich TM et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012;44:981–990.
54. Flannick J, Thorleifsson G, Beer NL et al. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat Genet 2014;46:357–363.
55. Chen R, Shi L, Hakenberg J et al. Analysis of 589,306 genomes identifies individuals resilient to severe Mendelian childhood diseases. Nat Biotechnol 2016;34:531–538.